Phase III LINC 4 Study Confirms Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease

May 11, 2022

Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Hammer Wins Inaugural Endocrine Images Art Competition

Levels of AMH Could Predict or Detect Bone Loss in Premenopausal Women→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today